About the Authors

Viviane D. Lima

vlima@cfenet.ubc.ca

Affiliations British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, Department of Medicine, Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Isabell Graf

Affiliation Department of Mathematics, Simon Fraser University, Burnaby, Canada

Curt G. Beckwith

Affiliation Alpert Medical School of Brown University, The Miriam Hospital, Providence, Rhode Island, United States of America

Sandra Springer

Affiliation Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, Connecticut, United States of America

Frederick L. Altice

Affiliations Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, Connecticut, United States of America, Yale University School of Public Health, Division of Epidemiology of Microbial Diseases, New Haven, Connecticut, United States of America

Daniel Coombs

Affiliation Department of Mathematics, University of British Columbia, Vancouver, British Columbia, Canada

Brian Kim

Affiliation Rollins School of Public Health Department of Epidemiology, Emory University School of Medicine, Atlanta, United States of America

Lauren Messina

Affiliation Rollins School of Public Health Department of Epidemiology, Emory University School of Medicine, Atlanta, United States of America

Julio S. G. Montaner

Affiliations British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, Department of Medicine, Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Anne Spaulding

Affiliation Rollins School of Public Health Department of Epidemiology, Emory University School of Medicine, Atlanta, United States of America

Competing Interests

JM has received limited unrestricted funding, paid to his institution, from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. VDL has received limited unrestricted funding, paid to her institution, from GlaxoSmithKline. AS has received grants through Emory University from Boehringer Ingelheim, Bristol Myers Squibb, and Gilead Sciences, and has, as an individual, consulted for Gilead Sciences and Janssen Pharmaceuticals. FA has received limited unrestricted funding, paid to his institution, from Gilead Sciences, has currently funded research from Merck, and has received donated medications for research studies from Alkermes and Reckitt Benkisser. He has, as an individual, consulted for Bristol-Myers Squibb. The remaining authors report no conflict of interest.

Author Contributions

Conceived and designed the experiments: VDL AS. Performed the experiments: VDL IG DC. Analyzed the data: VDL IG. Contributed reagents/materials/analysis tools: VDL AS JM BK LM. Wrote the paper: VDL IG CB SS DC JM AS FA BK LM. Obtained funding: VDL AS CB FA JM. Administrative, technical, or material support: VDL JM. Study supervision: VDL AS.